Pembrolizumab and Epacadostat in Treating Patients With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma



Status:Recruiting
Conditions:Ovarian Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:September 28, 2018
End Date:April 30, 2021

Use our guide to learn which trials are right for you!

A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary

This phase II trial studies how well pembrolizumab and epacadostat work in treating patients
with ovarian clear cell carcinoma that has come back, remains despite treatment, or is
growing, spreading, or getting worse. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Epacadostat may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and epacadostat
may work better in treating patients with ovarian clear cell carcinoma.

PRIMARY OBJECTIVES:

I. To assess the objective tumor response (proportion of objective response by Response
Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) of the combination of
pembrolizumab (MK-3475 [pembrolizumab]) and epacadostat in patients with recurrent or
persistent clear cell carcinoma of the ovary.

SECONDARY OBJECTIVES:

I. To determine the nature and degree of toxicity of MK-3475 (pembrolizumab) + epacadostat as
assessed by Common Terminology Criteria for Adverse Events (CTCAE) in patients with recurrent
or persistent clear cell carcinoma of the ovary.

II. To estimate the progression-free survival (PFS) and overall survival (OS) in patients
treated with combination of MK-3475 (pembrolizumab) and epacadostat.

EXPLORATORY TRANSLATIONAL OBJECTIVES:

I. Determine whether the ratio of plasma tryptophan to kynurenine (T:K) correlates with
response to MK-3475 (pembrolizumab) + epacadostat, by evaluating plasma T:K pre-treatment,
during treatment, and at disease progression.

II. Determine whether the presence of PD-L1, IDO-1, tumor-infiltrating regulatory T cells
(Tregs), CD8 tumor-infiltrating lymphocytes (TILs), and human leukocyte antigen (HLA) class I
in the tumor microenvironment at baseline correlates with objective response to MK-3475
(pembrolizumab) + epacadostat.

III. Determine whether soluble PD-L1 (sPD-L1) levels in plasma are correlated with response
to MK-3475 (pembrolizumab) + epacadostat, by evaluating sPD-L1 concentrations pre-treatment,
during treatment, and at disease progression.

OUTLINE:

Patients receive epacadostat orally (PO) twice daily (BID) and pembrolizumab intravenously
(IV) over 30 minutes once every 3 weeks (Q3W). Cycles repeat every 21 days in the absence of
disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years,
then every 6 months for 3 years, and annually thereafter.

Inclusion Criteria:

- Primary tumors must be at least 50% clear cell histomorphology in order to be eligible
or have a histologically documented recurrence with at least 50% clear cell
histomorphology. Recurrence should be biopsy proven as per standard of care unless the
tumor is located in an area deemed unsafe to biopsy. Histologic confirmation of the
original primary tumor is required via the pathology report. The percentage of clear
cell histomorphology must be documented in the pathology report or in an addendum to
the original report. If slides of the primary tumor are not available for review due
to disposal of slides by the histology laboratory (typically 10 years after
diagnosis), a biopsy of the recurrent or persistent tumor is required to confirm at
least 50% clear cell histomorphology, as long as tumor is located in an area deemed
safe to biopsy. The percentage of clear cell involvement must be documented in the
pathology report or in an addendum to the original report

- All patents must have measurable disease, and at least one "target lesion" to be used
to assess response as defined by RECIST 1.1. Measurable disease is defined as at least
one lesion that can be accurately measured in at least one dimension (longest diameter
to be recorded). Each lesion must be >= 10 mm when measured by computed tomography
(CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >=
20 mm when measured by chest x-ray. Lymph nodes must be >= 15 mm in short axis when
measured by CT or MRI

- Appropriate stage for study entry based on the following diagnostic workup:

- History/physical examination within 28 days prior to registration

- Imaging of target lesions within 28 days prior to registration

- Further protocol-specific assessments

- Recovery from adverse effects of recent surgery, radiotherapy or
chemotherapy

- Any other prior therapy directed at the malignant tumor including
chemotherapy, and biologic/targeted agents must be discontinued at least 4
weeks prior to registration. Any hormonal therapy directed at the malignant
tumor must be discontinued at least 2 weeks prior to registration

- Any prior radiation therapy must be completed at least 4 weeks prior to
registration, and progression must be outside the radiation field

- At least 4 weeks must have elapsed since any major surgery prior to
registration

- The trial is open only to women with recurrent or progressive clear cell carcinoma of
the ovary

- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0 or 1 within 28 days prior to registration

- Patients must have had one prior platinum-based chemotherapy for management of primary
disease. Patients are allowed to receive, but are not required to receive, up to two
additional cytotoxic regimens for management of recurrent or persistent disease

- Absolute neutrophil count (ANC) >= 1,500/ul (within 14 days prior to registration)

- Platelets >= 100,000/ul (within 14 days prior to registration)

- Hemoglobin (Hgb) >= 8.0 g/dL within 14 days prior to registration (Note: the use of
transfusion of other intervention to achieve a Hgb >= 8.0 g/dL is acceptable)

- Creatinine =< 1.5 x institutional upper limit of normal (ULN) or creatinine clearance
(CrCl) >= 60 mL/min using Cockcroft-Gault formula (within 14 days prior to
registration)

- Bilirubin =< 2.5 x ULN (within 14 days prior to registration)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
(within 14 days prior to registration)

- Normal thyroid function testing (thyroid-stimulating hormone [TSH]) (within 14 days
prior to registration)

- Negative pregnancy test in women of childbearing potential

- Women of childbearing potential who are sexually active should be willing and able to
use medically acceptable forms of contraception for the course of the study through
120 days after the last dose of MK-3475 (pembrolizumab). Women who are not of
childbearing potential (i.e., who are postmenopausal or surgically sterile, who have
had a hysterectomy and/or bilateral oophorectomy) do not require contraception

- The patient or a legally authorized representative must provide study-specific
informed consent prior to study entry

Exclusion Criteria:

- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
for a minimum of 3 years

- Patients who have had prior therapy with MK-3475 (pembrolizumab) or epacadostat or
with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody
or drug specifically targeting T-cell co-stimulation or immune check point pathways

- History of severe hypersensitivity reaction to any monoclonal antibody

- Patients with active auto-immune disease or history of autoimmune disease that might
recur, which may affect vital organ function or require immune suppressive treatment
including systemic corticosteroids, should be excluded. These include but are not
limited to patients with a history of immune related neurologic disease, multiple
sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia
gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE),
connective tissue diseases, scleroderma, inflammatory bowel disease, Crohn's,
ulcerative colitis, hepatitis; and patients with a history of toxic epidermal
necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be
excluded because of the risk of recurrence or exacerbation of disease. Patients with
vitiligo, endocrine deficiencies including thyroiditis managed with replacement
hormones including physiologic corticosteroids are eligible. Patients with rheumatoid
arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with
topical medication and patients with positive serology, such as antinuclear antibodies
(ANA), anti-thyroid antibodies should be evaluated for the presence of target organ
involvement and potential need for systemic treatment but should otherwise be eligible

- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
or active infection, symptomatic congestive heart failure and unstable angina
pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements

- Patients with history or evidence upon physical examination of central nervous system
(CNS) disease, including primary brain tumor, seizures which are not controlled with
non-enzyme inducing anticonvulsants, and/or epidural disease, or history of
cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or
subarachnoid hemorrhage within six months prior to the first date of study treatment.
Those with brain metastases are permitted as long as they have been treated with brain
radiation therapy and have been documented stability 4 weeks following completion of
brain radiation therapy

- In order for patients with human immunodeficiency virus (HIV) or known acquired
immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly
active antiretroviral therapy (HAART) regimen with no drug-drug interaction with
UGT1A9, have CD4+ counts > 350, with no detectable viral load on quantitative
polymerase chain reaction (PCR), and no opportunistic infection

- Patients with treated hepatitis viral infections (hepatitis B and C) are eligible if
they have completed definitive treatment at least 6 months prior, have no detectable
viral load on quantitative PCR, and liver function tests (LFTs) meet eligibility
requirements

- Patients with a condition requiring systemic treatment with either corticosteroids (>
10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
days of study drug administration

- Therapy with monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake
inhibitor (SSRIs) within the last 4 weeks or history of serotonin syndrome.
Concomitant use of monoamine oxidase inhibitors with epacadostat (INCB024360) is
prohibited

- Patients who have had evidence of active or acute diverticulitis, intra-abdominal
abscess, abdominal/pelvic fistula, gastrointestinal perforation, gastrointestinal (GI)
obstruction and/or who require parenteral hydration and/or nutrition

- Epacadostat (INCB024360) is a substrate of CYP3A4, CYP1A2, CYP2C19, UGT1A9, P-gp, and
BCRP. Use caution when administered with strong inhibitors/inducers of these
isoenzymes and transporter proteins. Because the lists of these agents are constantly
changing, it is important to regularly consult a frequently-updated medical reference

- History or presence of an abnormal electrocardiography (ECG) that, in the
investigator's opinion, is clinically meaningful. Screening QTc interval > 480
milliseconds is excluded (corrected by Fridericia). In the event that a single QTc is
> 480 milliseconds, the subject may enroll if the average QTc for the 3 ECGs is < 480
milliseconds. For subjects with an intraventricular conduction delay (QRS interval >
120 msec), the JTc interval may be used in place of the QTc with sponsor approval. The
JTc must be < 340 milliseconds if JTc is used in place of QTc. Subjects with left
bundle branch block are excluded

- Patients who are pregnant or nursing
We found this trial at
351
sites
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Sarah F. Adams
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Linda R. Duska
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Kristin K. Zorn
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Dan S. Zuckerman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Dan S. Zuckerman
Phone: 206-215-3086
?
mi
from
Seattle, WA
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Principal Investigator: David C. Starks
Phone: 888-634-7268
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
Principal Investigator: Michael E. Carney
Phone: 808-486-6000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Michael E. Carney
Phone: 808-487-7447
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
Principal Investigator: Michael E. Carney
Phone: 808-678-9000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Michael E. Carney
Phone: 808-539-2273
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Dan S. Zuckerman
Phone: 360-412-8958
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
200-298 Avenida Doctor Pedro Albizu Campos
Aguadilla, 00603
Principal Investigator: Luis Baez-Diaz
Phone: 787-997-2222
?
mi
from
Aguadilla,
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
Principal Investigator: Sarah F. Adams
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 412-339-5294
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-2388
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
?
mi
from
Ballwin, MO
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Stephanie L. Gaillard
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Steven E. Waggoner
Phone: 800-641-2422
?
mi
from
Beachwood, OH
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Dan S. Zuckerman
Phone: 360-715-4133
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Dan S. Zuckerman
Phone: 541-706-2909
?
mi
from
Bend, OR
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
?
mi
from
Billings, MT
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Dan S. Zuckerman
Phone: 412-339-5294
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Boulder, CO
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
?
mi
from
Branson, MO
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bryan, TX
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Dan S. Zuckerman
Phone: 818-847-4793
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Burien, WA
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Brooke A. Schlappe
Phone: 414-302-2304
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Dan S. Zuckerman
Phone: 360-412-8958
?
mi
from
Centralia, WA
Click here to add this to my saved trials
Chardon, Ohio 44024
Principal Investigator: Steven E. Waggoner
Phone: 800-641-2422
?
mi
from
Chardon, OH
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Richard L. Deming
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Cheyenne, Wyoming 82001
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Cheyenne, WY
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: John W. Moroney
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: Timothy D. Moore
Phone: 877-779-7585
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
?
mi
from
Chillicothe, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Dan S. Zuckerman
Phone: 503-215-2614
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Dan S. Zuckerman
Phone: 503-215-2614
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
2500 Metrohealth Dr
Cleveland, Ohio 44109
(216) 778-7800
Principal Investigator: Kimberly E. Resnick
Phone: 216-778-8526
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Peter G. Rose
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Steven E. Waggoner
Phone: 800-641-2422
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: Peter G. Rose
Phone: 866-223-8100
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
?
mi
from
Clive, IA
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Clive, IA
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Cody, WY
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
1400 West 4th Street
Coffeyville, Kansas 67337
Principal Investigator: Andrea D. Jewell
Phone: 620-252-1606
?
mi
from
Coffeyville, KS
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Floor Backes
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
5100 W Broad St
Columbus, Ohio 43228
(614) 544-1000
Principal Investigator: Timothy D. Moore
Phone: 614-566-3275
Doctors Hospital Nationally recognized for care quality and patient safety and satisfaction, Doctors Hospital is...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Columbus, Ohio 43213
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
(614) 383-6000
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
111 S Grant Ave
Columbus, Ohio 43215
(614) 566-9000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Grant Medical Center Founded in 1900 in Columbus' downtown, Grant has grown into one of...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
810 Jasonway Avenue
Columbus, Ohio 43214
614/442-3130
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
Columbus Oncology and Hematology Associates Inc Columbus Oncology and Hematology Associates is a group of...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Columbus, Ohio 43222
Principal Investigator: Timothy D. Moore
Phone: 614-234-5433
?
mi
from
Columbus, OH
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
?
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Coos Bay, Oregon 97420
Principal Investigator: Dan S. Zuckerman
Phone: 541-269-8392
?
mi
from
Coos Bay, OR
Click here to add this to my saved trials
1475 Northwest 12th Avenue
Coral Gables, Florida 33146
Principal Investigator: Brian M. Slomovitz
Phone: 305-243-2647
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Corbin, Kentucky 40701
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Corbin, KY
Click here to add this to my saved trials
Council Bluffs, Iowa 51503
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Creston, Iowa 50801
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Creston, IA
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 800-446-5532
?
mi
from
Danville, IL
Click here to add this to my saved trials
561 W. Central Avenue
Delaware, Ohio 43015
(740) 615-1000
Principal Investigator: Timothy D. Moore
Phone: 740-615-2403
Grady Memorial Hospital As the center of healthcare in Delaware County, Grady Memorial Hospital is...
?
mi
from
Delaware, OH
Click here to add this to my saved trials
Delaware, Ohio 43015
Principal Investigator: Timothy D. Moore
Phone: 412-339-5294
?
mi
from
Delaware, OH
Click here to add this to my saved trials
561 West Central Avenue
Delaware, Ohio 43015
(740) 615-1000
Principal Investigator: Timothy D. Moore
Phone: 740-615-0227
Delaware Health Center-Grady Cancer Center As the center of healthcare in Delaware County, Grady Memorial...
?
mi
from
Delaware, OH
Click here to add this to my saved trials
4567 E 9th Ave
Denver, Colorado 80220
(303) 320-2121
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Rose Medical Center Well known as a Denver institution and a 9th Avenue landmark for...
?
mi
from
Denver, CO
Click here to add this to my saved trials
2525 S Downing St
Denver, Colorado 80210
(303) 778-1955
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Porter Adventist Hospital Founded in 1930, Porter Adventist Hospital has provided people throughout Denver and...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
720-754-4800
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials